Authors
YY Janjigian, D Werner, Cet al Pauligk, K Steinmetz, DP Kelsen, E Jäger, HM Altmannsberger, E Robinson, LJ Tafe, LH Tang, MA Shah, S-E Al-Batran
Publication date
2012/10/1
Journal
Annals of oncology
Volume
23
Issue
10
Pages
2656-2662
Publisher
Elsevier
Description
Background
To determine whether human epidermal growth factor receptor 2 (HER2) status is an independent prognostic factor in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Patients and methods
Formalin-fixed paraffin-embedded tumor samples from 381 metastatic gastric/GEJ cancer patients enrolled at Krankenhaus Nordwest and Memorial Sloan–Kettering Cancer Centers on six first-line trials of chemotherapy without trastuzumab were examined for HER2 by immunohistochemistry (IHC) and in situ hybridization (ISH). IHC 3+ or ISH-positive tumors were considered HER2 positive.
Results
Seventy-eight of 381 patients (20%) had HER2-positive disease. In the multivariate logistic model, there were significantly higher rates of HER2 positivity in patients with liver metastasis (liver metastasis 31%; no liver metastasis 11%; P = 0.025) and intestinal histology (intestinal 33%; diffuse/mixed …
Total citations
Scholar articles
YY Janjigian, D Werner, C Pauligk, K Steinmetz… - Annals of oncology, 2012